MyOme Launches Free Genetic Testing Program for ADH1 Families

  • MyOme launched CASRcade, a no-charge family cascade genetic testing program for U.S. families affected by Autosomal Dominant Hypocalcemia Type 1 (ADH1).
  • The program offers free familial variant testing (FVT) and genetic counseling for biological relatives up to fourth degree of confirmed ADH1 patients.
  • Sponsored by BridgeBio, CASRcade aims to identify relatives carrying the CASR gene variant associated with ADH1 for earlier diagnosis and care.
  • MyOme will perform targeted genetic sequencing and facilitate access to genetic counseling for positive results.

MyOme's CASRcade program addresses a critical gap in genetic testing for rare diseases, leveraging its whole-genome analysis platform to provide actionable insights. The initiative aligns with broader trends in preventive healthcare and the growing emphasis on family-based genetic screening. The partnership with BridgeBio underscores the strategic importance of collaborative efforts in advancing rare disease diagnostics.

Program Adoption
How quickly healthcare providers and families will enroll in the CASRcade program, given the no-charge model.
Diagnostic Impact
Whether the program will significantly increase early diagnoses of ADH1 among at-risk relatives.
Strategic Partnerships
The potential for BridgeBio to expand its collaboration with MyOme beyond this program.